TY  - BOOK
AU  - Mostafa Maher Elgammal
AU  - Alfred Elias Namour , 
AU  - Hanan Ramadan Nassar , 
AU  - Ihab Samy Fayek , 
TI  - Neoadjuvant versus adjuvant chemotherapy in advanced ovarian carcinoma / 
PY  - 2017///
CY  - Cairo : 
PB  - Mostafa Maher Elgammal , 
KW  - Advanced ovarian carcinoma
KW  - Completecyto
KW  - Neoadjuvant chemotherapy
N1  - Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology(Medical); Issued also as CD
N2  - Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. The aim of this retrospective study was to assess whether there is an advantage of treating women with advanced ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery. Methods and materials: Include patients with advanced epithelial ovarian cancer (stage III and IV) who underwent surgery from 2009-2015 with optimal cyto-reductive surgery (R0). Results: The study included 60 patients the mean age for all the patients was 53.7 years . A total of 60 patients diagnosed and treated in NCI and Agouza Police hospital in the specified period (2009-2015), with locally advanced epithelial ovarian carcinoma. They are divided into 2 groups according to pattern of treatment where 30 patients seemed resectable and primary cytoreductive surgery was carried out, and 30 patients seemed unresectable and neoadjuvant chemotherapy was given to them. On assessment of the survival we compared the whole number of both groups. The median overall survival time was 45.77 months in the conventional group and 49.06 month in the NACT group
UR  - http://172.23.153.220/th.pdf
ER  -